| Patient | Arthur Ashe |
|---|---|
| Date of birth | 1980-07-10 |
| Identifiers | MRN HR-ML013-SYN; SSN (made up) 000-13-6620 |
| Document date | 2026-04-13 |
| Author | Vivian Tolliver, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month HIV and lipid review. [S]
Mr. Ashe returns three months after his first visit, about seven months after starting antiretroviral therapy. He has missed no doses. He has had no headache, weakness, rash, fever, or chest pain. He is coaching four afternoons a week and hitting balls three times a week without angina. He has had no muscle aches on atorvastatin and ezetimibe. His blood tests were drawn this morning. He left before giving a urine sample, so the urine albumin test ordered at the last visit was not done. He feels more like himself and says that worry about his privacy comes and goes. [S]
| Element | Detail |
|---|---|
| Adherence | No missed doses |
| Activity | Coaching four afternoons a week; tennis drills without angina |
| Side effects | None |
| Urine test | Not collected this morning |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or night sweats; weight up 1.2 kg |
| Cardiovascular | Negative | No chest pain or palpitations |
| Musculoskeletal | Negative | No muscle aches |
| Neurological | Negative | No headache, seizure, or weakness |
| Psychiatric | Negative | Mood good; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium | One tablet by mouth once daily | Oral route | 2025-09-25 | active | S |
| Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intake | Three tablets by mouth daily after a 200 mg loading dose | Oral route | 2025-09-11 to 2025-10-23 | completed | S |
| Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intake | Three tablets by mouth every 6 hours | Oral route | 2025-09-11 to 2025-10-23 | completed | S |
| Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intake | Two tablets by mouth daily | Oral route | 2025-09-11 to 2025-10-23 | completed | S |
| Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2025-10-23 to 2026-10-19 | completed | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2016-07-31 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2016-08-01 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 2016-08-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-13 | Body height | 185 | cm | S |
| 2026-04-13 | Body weight | 73.8 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 68 | /min | S |
| 2026-04-13 | Respiratory rate | 14 | /min | S |
| 2026-04-13 | Body temperature | 36.7 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-13 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | {copies}/mL | Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected | Normal | S |
| 2026-04-13 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 218 | /uL | 500-1500 /uL | Low | S |
| 2026-04-13 | Leukocytes [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-13 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-04-13 | Platelets [#/volume] in Blood by Automated count | 224 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-13 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.15 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 80 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-13 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-56 U/L | Normal | S |
| 2026-04-13 | Cholesterol [Mass/volume] in Serum or Plasma | 118 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 41 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-04-13 | Triglyceride [Mass/volume] in Serum or Plasma | 125 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-04-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 52 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-04-13 | Lipoprotein a [Mass/volume] in Serum or Plasma | 24 | mg/dL | <=29 mg/dL | Normal | S |
| 2026-04-13 | Hepatitis B virus surface Ab [Units/volume] in Serum | 86 | m[IU]/mL | >=10 m[IU]/mL | Normal | S |
Vital signs recorded on 2026-04-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 73.8 kg, blood pressure 120/74 |
| Mouth | No thrush |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Neurological | Grip and fine finger movements equal on both sides |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infection | active | confirmed | B20 | S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled. |
| Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapy | active | confirmed | B58.2 | S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass. |
| Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1979 and 1983 operations | active | confirmed | I25.10 | S — Synthetic modern diagnosis; the history remains D. |
| Old myocardial infarction at age 36 | active | confirmed | I25.2 | S — Synthetic coded history of the documented 1979 heart attack. |
| Hyperlipidemia, on high-intensity statin | active | confirmed | E78.5 | S — Synthetic diagnosis; no cholesterol value from his lifetime is used. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HIV-1 viral load | 4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 months | Completed today | Not detected (below 20 copies/mL), from 42 three months ago |
| Laboratory | CD4 count | Every 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ART | Completed today | 218 cells/uL, above 200 for the first time |
| Medication safety | ART adherence and drug-interaction review (antacids, calcium, iron, new medicines) | Every visit | Completed today | No missed doses; no interacting medicines |
| Laboratory | Complete blood count | Every 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ART | Completed today | Hemoglobin 13.6 g/dL, white cells 4.6, platelets 224 |
| Laboratory | Potassium, creatinine, and eGFR | 1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 months | Completed today | Potassium 4.7 mmol/L, creatinine 1.15 mg/dL, eGFR 80 |
| Laboratory | Urine albumin-to-creatinine ratio on tenofovir | At the start of tenofovir and yearly | Deferred | Ordered after the deviation recorded at the four-week visit, but the sample was not collected this morning: a second miss. Creatinine is stable, so no harm is evident. Corrective action: the urine sample is now part of the standing order for each blood draw, starting at six months |
| Laboratory | ALT | Every 6 months on ART; with symptoms on a statin | Completed today | ALT 27 U/L |
| Medication safety | Toxoplasma maintenance therapy and stopping criteria | Continue until CD4 above 200 for more than 6 months on ART with a suppressed viral load | Completed today | CD4 above 200 for the first time; continue for at least six more months |
| Medication safety | Pneumocystis prophylaxis | While CD4 below 200; stop after more than 3 months above 200 | Completed today | Covered by the maintenance dose |
| Examination | Neurological check: headache, seizure, weakness, and right-hand strength | Every visit | Completed today | No symptoms; strength equal |
| Laboratory | Hepatitis B vaccine series and antibody check | Two doses four weeks apart; surface antibody 1 to 2 months after the last dose | Completed today | Surface antibody 86 mIU/mL nine weeks after dose 2: protected |
| Self-management | Meningococcal ACWY vaccine | Two doses at least 8 weeks apart, then every 5 years | Completed today | Dose 2 given today, thirteen weeks after dose 1; booster in five years |
| Self-management | Recombinant zoster vaccine | Two doses 2 to 6 months apart, from age 18 with HIV | Completed today | Dose 1 given today |
| Self-management | Psychosocial support, disclosure on his terms, and U=U counseling | Every visit | Completed today | Worry about privacy comes and goes; U=U explained; peer support offered again |
| Survey | Depression screen (PHQ-9 or PHQ-2) | At intake, at six months, and yearly | Up to date | PHQ-9 5 at intake; mood good; next at six months |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 120/74 mmHg |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 73.8 kg, BMI 21.6; regaining weight lost during his illness |
| Self-management | Tobacco use | Every visit | Completed today | Never used tobacco |
| Medication safety | Coronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibe | Every visit | Completed today | Taking all three; no muscle aches |
| Self-management | Angina review and chest-pain plan | Every visit | Completed today | No angina with tennis drills; nitroglycerin not used |
| Laboratory | Lipid panel | 4 to 12 weeks after a change, then every 3 to 12 months; yearly when stable | Completed today | LDL 52 mg/dL, at goal; drawn 13 weeks after the change, one week outside the window, with no effect on care |
| Laboratory | Lipoprotein(a), once in adulthood | Once in adulthood | Completed today | 24 mg/dL, not elevated; no repeat needed |
| Imaging | Stress testing, coronary imaging, or echocardiography | Only with new or worsening symptoms; routine surveillance not recommended | Not indicated | No symptoms |
Goal progress:
Immunizations given today: Meningococcal conjugate vaccine MenACWY, dose 2 of 2; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026)
Follow-up: Six-month visit with viral load, CD4 count, metabolic panel, urine albumin, and the PHQ-9. Results by secure message. Next scheduled visit 2026-07-13: six-month HIV and coronary disease review with depression screening. [S]